Full Text View
Tabular View
No Study Results Posted
Related Studies
Pegylated Recombinant Mammalian Uricase (PEG-uricase) as Treatment for Refractory Gout
This study has been completed.
Study NCT00111657   Information provided by Duke University
First Received: May 24, 2005   Last Updated: July 10, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Gout
More general conditions related to this trial
Arthritis
Genetic Diseases, Inborn
Joint Diseases
Metabolic Diseases
Metabolism, Inborn Errors
Musculoskeletal Diseases
Purine-Pyrimidine Metabolism, Inborn Errors
Rheumatic Diseases
Interventions listed in this trial
Pegloticase
Sponsors listed in this trial
Duke University
Savient Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services